INTS logo

Intensity Therapeutics (INTS) Company Overview

Profile

Full Name:

Intensity Therapeutics, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

June 30, 2023

Indexes:

Not included

Description:

INTS (Intensity Therapeutics) focuses on developing innovative cancer therapies using its proprietary drug delivery system. The company aims to enhance the effectiveness of cancer treatments by targeting tumors directly, minimizing side effects, and improving patient outcomes. Their approach seeks to revolutionize cancer care through advanced therapeutic solutions.

Events Calendar

Earnings

Next earnings date:

Mar 14, 2025

Recent quarterly earnings:

Nov 13, 2024

Recent annual earnings:

Mar 14, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Jan 13, 25 Alliance Global Partners
Buy
Nov 21, 24 HC Wainwright & Co.
Buy
Oct 31, 24 HC Wainwright & Co.
Buy
Jul 11, 24 Benchmark
Speculative Buy
May 16, 24 Benchmark
Speculative Buy
Mar 21, 24 Benchmark
Speculative Buy
Nov 14, 23 Benchmark
Speculative Buy
Aug 24, 23 Benchmark
Speculative Buy
Jul 18, 23 Benchmark
Speculative Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS)
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS)
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS)
INTS
prnewswire.comDecember 12, 2024

Enrollment is ongoing and seven sites in Switzerland have been activated SHELTON, Conn. and BERN, Switzerland , Dec. 12, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumorally injected cancer therapies intended to kill tumors directly and increase immune system recognition of cancers, and The Swiss Group for Clinical Cancer Research SAKK ("SAKK"), a decentralized academic research institute that has been conducting clinical trials of cancer treatments in all major Swiss hospitals since 1965, announced that Andreas Mueller, M.D.

Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting
Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting
Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting
INTS
prnewswire.comNovember 8, 2024

SHELTON, Conn. , Nov. 8, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), ("Intensity" or "the Company") a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumorally injected cancer therapies intended to kill tumors directly and increase immune system recognition of cancers, today announced that its Phase 3 trial has been selected for an oral podium presentation at the 2024 Connective Tissue Oncology Society (CTOS) on November 16, 2024.

Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
INTS
prnewswire.comAugust 8, 2024

First patient dosed in global randomized, Phase 3 study in metastatic soft tissue sarcoma Collaboration agreement with The Swiss Group for Clinical Cancer Research SAKK ("SAKK") to conduct a Phase 2 randomized, study in early-stage breast cancer in Europe Cash and investments of $6.3 million expected to fund operations into the first quarter of 2025 SHELTON, Conn. , Aug. 8, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces second quarter 2024 financial results and provides a corporate update.

Intensity Therapeutics to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update
Intensity Therapeutics to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update
Intensity Therapeutics to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update
INTS
PRNewsWireAugust 7, 2023

Webcast to be Held at 8:00 am ET on Monday, August 14, 2023 WESTPORT, Conn. , Aug. 7, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. (Intensity) (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced that it report its financial results for the second quarter ended June 30, 2023, including a corporate update, on Monday, August 14, 2023, before the opening of the U.S. financial markets.

FAQ

  • What is the ticker symbol for Intensity Therapeutics?
  • Does Intensity Therapeutics pay dividends?
  • What sector is Intensity Therapeutics in?
  • What industry is Intensity Therapeutics in?
  • What country is Intensity Therapeutics based in?
  • When did Intensity Therapeutics go public?
  • Is Intensity Therapeutics in the S&P 500?
  • Is Intensity Therapeutics in the NASDAQ 100?
  • Is Intensity Therapeutics in the Dow Jones?
  • When was Intensity Therapeutics's last earnings report?
  • When does Intensity Therapeutics report earnings?
  • Should I buy Intensity Therapeutics stock now?

What is the ticker symbol for Intensity Therapeutics?

The ticker symbol for Intensity Therapeutics is NASDAQ:INTS

Does Intensity Therapeutics pay dividends?

No, Intensity Therapeutics does not pay dividends

What sector is Intensity Therapeutics in?

Intensity Therapeutics is in the Healthcare sector

What industry is Intensity Therapeutics in?

Intensity Therapeutics is in the Biotechnology industry

What country is Intensity Therapeutics based in?

Intensity Therapeutics is headquartered in United States

When did Intensity Therapeutics go public?

Intensity Therapeutics's initial public offering (IPO) was on June 30, 2023

Is Intensity Therapeutics in the S&P 500?

No, Intensity Therapeutics is not included in the S&P 500 index

Is Intensity Therapeutics in the NASDAQ 100?

No, Intensity Therapeutics is not included in the NASDAQ 100 index

Is Intensity Therapeutics in the Dow Jones?

No, Intensity Therapeutics is not included in the Dow Jones index

When was Intensity Therapeutics's last earnings report?

Intensity Therapeutics's most recent earnings report was on Nov 13, 2024

When does Intensity Therapeutics report earnings?

The next expected earnings date for Intensity Therapeutics is Mar 14, 2025

Should I buy Intensity Therapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions